Related Experiment Video
Updated: Jan 17, 2026
Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade
Published on: August 14, 2019
Optimized Synthetic Flavonols Support Senescence Clearance and Lung Fibrosis Resolution
Jeffrey A Meridew1, John A Vu2,3, Daniela Chow4
1Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota 55902, United States.
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with undefined etiology and minimally effective therapies. The greatest risk factor for developing IPF is aging. The central paradigm to developing antifibrotic drugs for the last half century has focused on directly targeting proliferative lung fibroblasts. However, recent high-resolution analyses of IPF patient lungs suggests disease unique populations of resident lung cells are enriched for markers of senescence. Published work by our group and others further supports that senescent cells are key drivers of fibrosis and may provide an opportunity to develop an effective antifibrotic drug. Multiple naturally derived flavonoids can selectively induce apoptosis in senescent cells (senolytic) and improve end points in models of lung fibrosis; however, these natural phytochemicals are not structurally optimized to maximize their translational potential. Inspired by this opportunity we have performed hit-to-lead studies and medicinal chemistry optimization to generate a novel synthetic flavanoid (F-4N) with ∼ 50× greater senolytic potency in vitro- compared to fisetin or quercetin, two naturally derived senolytic flavonols. Furthermore, in bleomycin injury models of lung fibrosis we have shown treatment with F-4N (10 mg/kg-30 mg/kg, daily) promotes reduced senescence burden, resolution of chronic lung fibrosis, and markers of enhanced alveolar epithelial repair.
Insights
A novel synthetic flavonoid, F-4N, shows potent senolytic activity against senescent cells, offering a promising new therapeutic avenue for idiopathic pulmonary fibrosis (IPF) by reducing lung fibrosis and enhancing repair.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Drug Discovery
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with limited treatment options.
- Aging is the primary risk factor for IPF, and senescent cells are increasingly recognized as key drivers of fibrosis.
- Current antifibrotic drug development has primarily targeted lung fibroblasts, with limited success.
Purpose of the Study:
- To develop a novel, potent senolytic agent for IPF treatment.
- To investigate the therapeutic potential of a synthetic flavonoid, F-4N, in preclinical models of lung fibrosis.
Main Methods:
- Medicinal chemistry optimization was used to generate the synthetic flavonoid F-4N.
- In vitro senolytic activity of F-4N was compared to naturally derived flavonoids (fisetin, quercetin).
- Bleomycin-induced lung injury models were used to assess F-4N's efficacy in vivo.
Main Results:
- F-4N demonstrated approximately 50-fold greater in vitro senolytic potency compared to fisetin and quercetin.
- In vivo treatment with F-4N reduced senescence burden in a bleomycin-induced lung fibrosis model.
- F-4N treatment promoted the resolution of chronic lung fibrosis and enhanced alveolar epithelial repair.
Conclusions:
- The synthetic flavonoid F-4N is a potent senolytic agent with significant potential for IPF therapy.
- F-4N effectively reduces lung fibrosis and promotes repair in preclinical models.
- Targeting senescent cells with optimized synthetic flavonoids represents a promising strategy for treating IPF.
